Guardant Health - GH Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GH shares.
View GH analyst ratings or view top-rated stocks.

14 Wall Street analysts have issued 12 month price targets for Guardant Health's shares. Their GH share price forecasts range from $65.00 to $165.00. On average, they anticipate the company's stock price to reach $114.46 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts price targets for GH or view top-rated stocks among Wall Street analysts.

Guardant Health's stock was trading at $100.02 at the beginning of 2022. Since then, GH shares have decreased by 40.5% and is now trading at $59.52.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our GH earnings forecast.

Guardant Health, Inc. (NASDAQ:GH) posted its quarterly earnings results on Thursday, August, 4th. The company reported ($2.25) earnings per share for the quarter, missing the consensus estimate of ($1.25) by $1.00. The firm had revenue of $109.14 million for the quarter, compared to analysts' expectations of $105.14 million. Guardant Health had a negative trailing twelve-month return on equity of 99.90% and a negative net margin of 135.03%. The firm's quarterly revenue was up 18.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.96) earnings per share.

Guardant Health issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $460.00 million-$470.00 million, compared to the consensus revenue estimate of $465.29 million.

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Guardant Health's stock is owned by many different retail and institutional investors. Top institutional investors include Wedmont Private Capital (0.00%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Stanley J Meresman and Timothy P Eckersley.
View institutional ownership trends.

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GH stock can currently be purchased for approximately $59.52.

Guardant Health (NASDAQ:GH) has a market capitalization of $6.08 billion and generates $373.65 million in revenue each year. The company earns $-405,670,000.00 in net income (profit) each year or ($5.41) on an earnings per share basis.

The company employs 1,373 workers across the globe.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258.